Research Topics
Species | Marc BonacaSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
| Collaborators
|
Detail Information
Publications
Antithrombotics in acute coronary syndromes: updates from the past yearMarc Bonaca
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
Curr Treat Options Cardiovasc Med 12:84-99. 2010..Incremental updates to guideline recommendations from established expert groups will be important in providing guidance...
Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA2{degrees}P-TIMI 50Marc P Bonaca
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115
Circulation 127:1522-9. 2013..Patients with peripheral artery disease are at risk of systemic atherothrombotic events, as well as acute and chronic limb ischemia and the need for peripheral revascularization...- Management of asymptomatic carotid artery stenosisMarc P Bonaca
Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA, 02115, USA
Curr Treat Options Cardiovasc Med 15:252-63. 2013..The most important aspect of the management of asymptomatic carotid artery stenosis is reducing the overall cardiovascular risk of the patient... - Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromesMarc P Bonaca
Brigham and Women s Hospital, Boston, Massachusetts, USA
J Am Coll Cardiol 60:332-8. 2012..This study sought to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment in non-ST-segment elevation acute coronary syndrome (NSTE-ACS)... - American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Marc P Bonaca
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
Circulation 125:577-83. 2012..The prognostic implications of MI defined in the current era have not been well described... - Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22Marc P Bonaca
TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
Arterioscler Thromb Vasc Biol 31:203-10. 2011.... - Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin IMarc Bonaca
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 55:2118-24. 2010..The purpose of this study was to investigate the prognostic implications of low-level increases in cardiac troponin I (cTnI) using a current-generation sensitive assay in patients with suspected acute coronary syndrome (ACS)... - SCH 530348: a novel oral thrombin receptor antagonistMarc P Bonaca
TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
Future Cardiol 5:435-42. 2009..Two large Phase III clinical outcome trials are currently underway to evaluate the safety and efficacy of SCH 530348 for the management of acute coronary syndromes and the secondary prevention of atherothrombotic events... - Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)Marc P Bonaca
TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
Am J Cardiol 99:344-8. 2007..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication... - Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees PDavid A Morrow
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Am Heart J 158:335-341.e3. 2009..Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents... - Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in MyocardiDavid A Morrow
Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Circulation 119:2758-64. 2009..This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI... - Antithrombotics in acute coronary syndromesMarc P Bonaca
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
J Am Coll Cardiol 54:969-84. 2009..In addition to reviewing existing agents, we take a look forward at the most promising new antithrombotics currently in late-stage clinical development and their potential role in the context of ACS management... - Defining a role for novel biomarkers in acute coronary syndromesMarc P Bonaca
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Clin Chem 54:1424-31. 2008..Active investigation has brought forward an increasingly large number of novel candidate markers; however, few of these markers have yet to be incorporated into routine clinical use...